Precision Business Insights
Portfolio

 

Irritable Bowel Syndrome Drugs Market

: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Irritable Bowel Syndrome Drugs Market By  Condition (Irritable Bowel Syndrome for Constipation (Irritable Bowel Syndrome for Diarrhea, Others) By Drugs (Alosetron, Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies) and Geography

 

Market Outline: Irritable Bowel Syndrome Drugs Market

Irritable bowel syndrome is a gastrointestinal tract disorder characterized by stomach pain and alteration bowel habits. It hampers the regular development of intestinal muscle linings to move food along the tract. Based on the manifestations, the disorder can be mild to severe irritable bowel syndrome. The symptoms may include cramping, stomach torment, swelling and gas, mucus in the stool, constipation, and loose bowels. The exact reason for irritable bowel disease is not known however, it is related with increased awareness of body function, and unusual gastrointestinal tract movements. The diagnostic is performed by testing the stool and blood. Endoscopic procedures are also used in diagnosis of the syndrome.

 

Market Dynamics: Irritable Bowel Syndrome Drugs Market

Global irritable bowel syndrome is primarily driven by the increase in prevalence of the syndrome worldwide. In addition robust pipeline of drugs such as alizyme, ramosetron and activity of the market players including product launches and collaborations projected to boost the market growth over the forecast period. Furthermore, change in the lifestyles, increased stress and favorable reimbursement policies in treatment of the disease projected to bolster the market share. Moreover, developments healthcare diagnostic sector in identifying the underlying disease and better understanding of pathology of disease projected to positively impact the development of new drug treatments. However, high cost of development and stringent regulatory policies are expected to hamper the market growth over the forecast period.

 

Global irritable bowel syndrome drugs market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.

 

Market Scope: Irritable Bowel Syndrome Drugs Market

Irritable bowel syndrome market is segmented based on the type

 

Based on condition, the market is segmented into the following:

  • Irritable Bowel Syndrome – Constipation
  • Irritable Bowel Syndrome – Diarrhea
  • Others

Based on drug, the market is segmented into the following:

  • Alosetron
  • Eluxadoline
  • Linaclotide
  • Lubiprostone
  • Others

Based on distribution channel, the market is segmented into the following:

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

 

Geography

 

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

Regional Analysis

Geographically, global irritable bowel syndrome market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America irritable bowel syndrome market is projected to have the significant growth over the forecast period owing to the high prevalence rates of syndrome coupled with the well-established healthcare infrastructure and awareness in public related to syndrome. According to the Center for Disease Control and prevention (CDC), an estimated 3 million adults were diagnosed with irritable bowel syndrome in 2015. Asia Pacific market expected to gain the lucrative opportunity for growth owing to the development in healthcare infrastructure and huge base of patient pool. Market players in Asia Pacific region are adopting the strategies such as collaboration, new product launches and expansion to strengthen its position. For instance, in March 2017, Astellas Pharma Inc. has launched LINZESS tablets, a guanylate cyclase – receptor agonist to treat irritable bowel syndrome with constipation into Japan market. Europe market anticipated to have the notable growth rate owing to presence of the major market players and active development of drugs to treat the irritable bowel syndrome

 

Competition Assessment

Some of the players in the global irritable bowel syndrome market include:

 

  • Allergan Plc. (Ireland)
  • Lexicon Pharmaceuticals, Inc. (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Astellas Pharma Inc.
  • Pfizer Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Ironwood Pharmaceuticals, Inc. (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Ono Pharmaceutical Co., Ltd. (Japan)
  • Abbot Laboratories. (U.S.)
  • Takeda Pharmaceutical Company Ltd. (Japan)

 

Notable Market Developments

  • In April 2017, Takeda Pharmaceutical Company Limited and Finch Therapeutics has entered into the collaboration agreement to develop the microbiome therapeutics in inflammatory bowel disease